Telix根据指导报告了2025年的结果,并列举了临床进展、全球增长和2026年的强劲前景。 Telix reported 2025 results in line with guidance, citing clinical progress, global growth, and strong outlook for 2026.

Telix于2026年2月4日报告了2025年全年财务结果,根据先前的指导确认收入和收益。 Telix reported full-year 2025 financial results on February 4, 2026, confirming revenue and earnings in line with prior guidance. 该公司着重指出了在新型放射药品临床试验、越来越多的国际采用以及扩大战略伙伴关系以促进制造业和市场普及方面取得的进展。 The company highlighted progress in clinical trials for new radiopharmaceuticals, growing international adoption, and expanded strategic partnerships to boost manufacturing and market reach. 管理层在2026年保持了积极的前景,理由是管道发展强劲,业务改进,全球对精密药品的需求不断增加,资本分配或红利没有变动。 Management maintained a positive outlook for 2026, citing strong pipeline development, operational improvements, and rising global demand for precision medicine, with no changes to capital allocation or dividends announced.